Literature DB >> 10743797

Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection.

A Kessel1, I Rosner, E Zuckerman, T D Golan, E Toubi.   

Abstract

OBJECTIVE: To investigate whether antikeratin antibodies (AKA) could be useful in the differential diagnosis of patients with rheumatoid arthritis (RA) compared to patients with hepatitis C virus (HCV) associated polyarthritis, who are seropositive for rheumatoid factor (RF).
METHODS: AKA were assayed in 3 different groups of patients; all were RF seropositive: Group 1: 25 patients with HCV associated polyarthralgia or arthritis. Group 2: 33 patients with RA. Group 3: 13 patients with autoimmune disorders other than RA. Fifteen healthy individuals served as controls.
RESULTS: AKA were detected in 20/33 patients with RA (60.6%) compared to only 2/25 patients (8%) with HCV associated arthritis (p < 0.0001). AKA were observed in 2/13 patients of Group 3 (15.3%). These results were also statistically different from those of patients with RA (p = 0.008). AKA were not found in the sera of the healthy controls.
CONCLUSION: AKA is a useful marker to differentiate patients with RA from those with hepatitis C arthritis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10743797

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy.

Authors:  Wafaa M Ezzat; Hala M Raslan; Azza A Aly; Nahed A Emara; Manal M El Menyawi; Amr Edrees
Journal:  Rheumatol Int       Date:  2009-11-01       Impact factor: 2.631

Review 2.  Rheumatic manifestations of hepatitis C infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

3.  Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome.

Authors:  D Sène; P Ghillani-Dalbin; N Limal; V Thibault; T van Boekel; J-C Piette; P Cacoub
Journal:  Ann Rheum Dis       Date:  2006-03       Impact factor: 19.103

4.  Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement.

Authors:  Michele Bombardieri; Cristiano Alessandri; Giancarlo Labbadia; Cristina Iannuccelli; Francesco Carlucci; Valeria Riccieri; Vincenzo Paoletti; Guido Valesini
Journal:  Arthritis Res Ther       Date:  2004-01-29       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.